New bill in Georgia redefines access to medical cannabis for patients

Lawmakers in the U.S. state of Georgia have decided to expand access to the medical marijuana, with the bipartisan passage of a reform bill aimed at modernizing an already restrictive system.

A reform driven by patients' access issues

The bill, known as Senate Bill 220, was approved by a large majority in the Georgia House of Representatives. Its stated goal is clear: to improve a program that, according to many stakeholders, has failed to adequately meet patients’ needs.

Georgia’s medical cannabis program has faced criticism due to its limited scope, both in terms of eligible medical conditions and the types of products available. This reform seeks to address these shortcomings by broadening eligibility criteria and adapting regulations to better reflect actual medical practices.

One of the changes introduced by the bill is the expansion of eligible conditions. Patients suffering from lupus,’severe arthritis and severe insomnia may soon be eligible for treatment. The legislation also removes the requirement that certain diseases, such as cancer or the Parkinson's disease must be classified as «serious or terminal» to be eligible.

The bill also revises the way in which the limits on THC are regulated. Previously capped at a concentration of 5%, lawmakers decided against raising the threshold to 50%, as initially proposed. Instead, they introduced a limit based on the concentration of 12,000 milligrams of THC, thereby bringing it more in line with prescribing practices in conventional medicine.

Another step forward is the authorization of the vaporization as a method of administering medical cannabis—an option that has been prohibited under Georgian law until now. Patients over the age of 21 would be allowed to vape cannabis-based products, offering a faster-acting alternative to oral formulations. However, the law maintains strict restrictions: smoking cannabis, public consumption, and products such as edibles or candies will remain prohibited.

A cautious approach amid an ongoing debate

Despite widespread support, the reform has not allayed all concerns. Some lawmakers continue to question the level of scientific evidence justifying expanded access to medical marijuana, calling for further research and clearer regulatory frameworks.

At the federal level, the THC remains classified as an Annex I substance, although discussions regarding a possible reclassification are ongoing. At the same time, compounds such as CBD — widely associated with therapeutic benefits such as relief from epilepsy and anxiety — remain at the heart of the debate over medical cannabis.

The new bill builds on a decade of gradual reforms since the adoption of the The Haleigh’s Hope Act, which was the first to legalize low-THC oil in Georgia and laid the groundwork for the current program. Since then, the state has gradually expanded production and distribution, although patient advocates believe that progress has been too slow.

Before it takes effect, the bill must return to the Senate for final approval.